Risk factors for breast cancer

Midi Health Announces 50 State Availability for Employers

Retrieved on: 
Monday, October 30, 2023

LOS ALTOS, Calif., Oct. 30, 2023 /PRNewswire/ -- Midi Health, a virtual care clinic focused exclusively on women navigating midlife hormonal transition, today continued its rapid growth by announcing that its services will be available for employers in all 50 states as of January 2024.

Key Points: 
  • The leading virtual clinic delivering insurance-covered, expert care for women in perimenopause and menopause, Midi Health expands national footprint
    LOS ALTOS, Calif., Oct. 30, 2023 /PRNewswire/ -- Midi Health , a virtual care clinic focused exclusively on women navigating midlife hormonal transition, today continued its rapid growth by announcing that its services will be available for employers in all 50 states as of January 2024.
  • "We can't talk about women's success at work without talking about menopause," said Joanna Strober, CEO and co-founder of Midi Health.
  • "We are expanding rapidly to ensure that we can support employers and employees in all 50 states with Midi's care."
  • Midi provides holistic perimenopause and menopause care.

Midi Health and Memorial Hermann Collaborate to Expand Access to Expert Midlife Care for Women

Retrieved on: 
Wednesday, October 18, 2023

HOUSTON, Oct. 18, 2023 /PRNewswire/ -- Midi Health, a virtual care clinic focused exclusively on women navigating midlife hormonal transition, and Memorial Hermann Health System are collaborating to care for women in perimenopause and menopause.

Key Points: 
  • HOUSTON, Oct. 18, 2023 /PRNewswire/ -- Midi Health, a virtual care clinic focused exclusively on women navigating midlife hormonal transition, and Memorial Hermann Health System are collaborating to care for women in perimenopause and menopause.
  • As part of their commitment to supporting women in the Houston community, Memorial Hermann is working with Midi to extend the care their providers can give to women.
  • "With Midi Health, women now have an integrated solution to meet their full health care needs, in collaboration with their affiliated providers here at Memorial Hermann."
  • "We are excited to collaborate with Memorial Hermann to close the gap in care for the millions of women who experience symptoms of menopause," said Midi Health CEO and Co-founder Joanna Strober.

Midi Health Secures $14M Investment To Bring Expert Midlife Care for Women 40+

Retrieved on: 
Thursday, October 27, 2022

SAN FRANCISCO, Oct. 27, 2022 /PRNewswire/ -- Midi Health, a virtual care clinic making expert care accessible and affordable for all women experiencing the hormonal changes of midlife, today announced the completion of a $14 million seed investment co-led by Felicis and SemperVirens. Additional investment comes from leading women's health investors including Emerson Collective, Icon Ventures, Operator Collective, Muse Capital, Steel Sky Ventures and Anne and Susan Wojcicki. Currently providing insurance covered care for patients in California, Midi will leverage the new capital to expand operations nationwide and launch partnerships with some of the largest hospital systems in the country, as well as major U.S. employers.

Key Points: 
  • Midi closes this midlife care gap with virtual care guided by nationally recognized physicians and researchers who oversee a network of nurse practitioners trained in women's midlife health.
  • "Healthcare for women aged 40+ is one of the largest segments of healthcare that has not been transformed by digital health.
  • Midi Health is the only comprehensive virtual care clinic for women navigating midlife hormonal transition.
  • Midi supports women with expert care and hormonal and non-hormonal medications, supplements, lifestyle coaching, and vital preventative health guidance.

Biophytis: Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022

Retrieved on: 
Tuesday, April 19, 2022

ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field.

Key Points: 
  • ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field.
  • Jean Mariani, MD, PhD (Board Director) will give an oral presentation on the results of the Phase 2 SARA-INT trial for the treatment of Sarcopenia.
  • The Minimal Clinically Important Difference (MCID) for the 400MWT in sarcopenia is 0.1 m/s.
  • The objective is to have a FPI (First patient In) for this new study at the end of H2 2022.

Biophytis provides updates on Sarconeos (BIO101) clinical development

Retrieved on: 
Tuesday, April 12, 2022

This result is considered meaningful as the Minimal Clinically Important Difference (MCID) for the 400MWT in sarcopenia is 0.1 m/s.

Key Points: 
  • This result is considered meaningful as the Minimal Clinically Important Difference (MCID) for the 400MWT in sarcopenia is 0.1 m/s.
  • Stanislas Veillet, CEO of Biophytis, declares: "In 2021 Sarconeos BIO(101) reached a key milestone with the end of SARA phase 2 trial in Sarcopenia.
  • As a reminder, the COVA clinical programme (identifier clinicaltrials.gov: NCT04472728) is an international, multi-centre, double-blind, placebo-controlled, group-sequential and adaptive two-part study.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.

Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

Retrieved on: 
Wednesday, October 27, 2021

In the Brazil Abivertinib study, only 8% were in category 5, demonstrating a far less severely compromised population having been enrolled.

Key Points: 
  • In the Brazil Abivertinib study, only 8% were in category 5, demonstrating a far less severely compromised population having been enrolled.
  • In the US study, patients in category 5 treated with Abivertinib were discharged from the hospital 2 days sooner than those in the Control Group (8.6 vs. 10.6 days).
  • Overall, in both studies patients who were in category 5, but not in category
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.

Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

Retrieved on: 
Tuesday, October 19, 2021

With this approval, Dr. Reddys is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.

Key Points: 
  • With this approval, Dr. Reddys is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.
  • We are pleased with the Agencys approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity, says Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories.
  • We look forward to bringing a more affordable generic version of this drug to market for the benefit of patients.
  • Please refer to Lenalidomide Capsules 2.5 mg and 20 mg Package Insert for Black Box warning and important safety information.

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Retrieved on: 
Tuesday, October 12, 2021

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease(ADPKD).

Key Points: 
  • SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease(ADPKD).
  • Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.
  • These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Retrieved on: 
Monday, August 2, 2021

For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the markets most accurate hereditary cancer test.

Key Points: 
  • For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the markets most accurate hereditary cancer test.
  • MyRisk with RiskScore offers a breast cancer risk assessment designed to improve patient outcomes and help minimize healthcare disparities.
  • With traditional hereditary cancer tests, approximately 95% of women will test negative for high-risk gene mutations, but still have additional breast cancer risk factors that need to be managed.
  • Working with industry leading researchers, Myriad Genetics assessed data from more than 275,000 women to validate the use of an enhanced method for assessing polygenic breast cancer risk assessments like RiskScore in women across ancestries.

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

Retrieved on: 
Wednesday, July 28, 2021

The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients.

Key Points: 
  • The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients.
  • The Phase 1 clinical trial has received all necessary regulatory approvals in Switzerland and subject enrollment has been initiated.
  • MindMed plans to study an intravenous administration method [during its Phase 1 clinical trial] that would induce a stable and prolonged DMT experience.
  • Forward-looking information in this news release include, but are not limited to, statements regarding the start of MindMed's Phase 1 clinical trial of DMT, the successful outcome of the Phase 1 clinical trial, the ability to initiate a Phase 2 clinical trial of DMT, regulatory approvals, the effects of DMT, subject enrollment and the administration method of DMT.